Who is sponsoring NCT03623165?

NCT03623165 is sponsored by Endotronix, Inc..

What drugs are being tested in NCT03623165?

Interventions in NCT03623165: Cordella™ Heart Failure System.

What condition does NCT03623165 study?

NCT03623165 studies Heart Failure NYHA Class III.

Is NCT03623165 still recruiting?

NCT03623165 is currently terminated. Last updated 19 August 2019.

Last reviewed 2019-08-19 · How we verify

NCT03623165

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRODIGY Registry in NYHA Class III Heart Failure Patients

Terminated Last updated 19 August 2019

What this trial tests

trial testing Cordella™ Heart Failure System in Heart Failure NYHA Class III in 7 participants. Terminated before completion.

Timeline

1 August 2018

Primary endpoint
15 August 2019

15 August 2019

Quick facts

Lead sponsor	Endotronix, Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	7
Start date	1 August 2018
Primary completion	15 August 2019
Estimated completion	15 August 2019
Sites	4 locations across United States

Drugs / interventions tested

Cordella™ Heart Failure System

Conditions studied

Heart Failure NYHA Class III — all drugs for Heart Failure NYHA Class III →

Sponsor

Endotronix, Inc. — full company profile →

Who can join

18 and older, any sex, with Heart Failure NYHA Class III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, prospective, single arm, multi-center registry to evaluate the Cordella™ Heart Failure System (CHFS) in up to 250 NYHA Class III HF patients .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cordella™ Heart Failure System

Trials testing the same drug.

NCT03375710 — SIRONA Trial Heart Failure NYHA Class III · NA · completed

Other recruiting trials for Heart Failure NYHA Class III

Currently open trials in the same condition.

NCT06791850 — Sustaining Home Heart Failure Palliative Care in Rural Appalachia · NA · recruiting
NCT06783335 — Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure · recruiting
NCT07399587 — Optimizing HFrEF Patients Using BaroStim and CardioMems · Phase 2, PHASE3 · recruiting
NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting
NCT04829617 — Promoting Well-being and Health in Heart Failure · NA · recruiting

Other Endotronix, Inc. trials

Trials by the same sponsor.

NCT06783335 — Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure · recruiting
NCT03375710 — SIRONA Trial Heart Failure NYHA Class III · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03623165 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endotronix, Inc.
Last refreshed: 19 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03623165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing